Company Description
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally.
The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors.
The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics.
IceCure Medical Ltd was incorporated in 2006 and is headquartered in Caesarea, Israel.
| Country | Israel |
| Founded | 2006 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 69 |
| CEO | Eyal Shamir |
Contact Details
Address: 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel | |
| Phone | 972 4 623 0333 |
| Website | icecure-medical.com |
Stock Details
| Ticker Symbol | ICCM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $0.00 |
| CIK Code | 0001584371 |
| CUSIP Number | M53071136 |
| ISIN Number | IL0011224156 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Eyal Shamir | Chief Executive Officer and Director |
| Ronen Tsimerman CPA | Chief Financial Officer |
| Shay Levav | Chief Operating Officer |
| Tlalit Bussi Tel-Tzure | Vice President of Business Development and Global Marketing |
| Shad Good | Vice President of Sales for North America |
| Merav Nir Dotan | Vice President of Human Resources |
| Galit Malik | Vice President of Operations and Service |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2026 | 6-K | Report of foreign issuer |
| Apr 21, 2026 | 6-K | Report of foreign issuer |
| Apr 10, 2026 | EFFECT | Notice of Effectiveness |
| Apr 1, 2026 | F-1 | Registration statement for certain foreign private issuers |
| Mar 31, 2026 | D | Notice of Exempt Offering of Securities |
| Mar 27, 2026 | 424B5 | Filing |
| Mar 27, 2026 | SCHEDULE 13D/A | Filing |
| Mar 27, 2026 | 6-K | Report of foreign issuer |
| Mar 25, 2026 | 6-K | Report of foreign issuer |
| Mar 24, 2026 | EFFECT | Notice of Effectiveness |